Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (606)	3/15/2005 12:11:18 PM
From: Icebrg	Read Replies (1) \| Respond to of 946

Ian Xyotax is paclitaxel repackaged as a prodrug. Among the advantages claimed for the drug is its supposed improved selectively. Therefore, Xyotax should primarily be seen as a paclitaxel replacement. For indications where paclitaxel has an effect, Xyotax was (is?) supposed to work better. It was also claimed that Xyotax should be able to avoid the MDR phenomena. If that is indeed the case, it might also be possible to use the drug in situations where paclitaxel is not useful due to the Pgp-pump effect. One such indication might be colon cancer, where the MDR-effect is strong and the taxanes don't bring much benefit. In the light of the current situation, we don't know however, to what extent, if at all, Xyotax might serve as a replacement for paclitaxel. Erik